About oramed pharmaceuticals inc. - ORMP
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It concentrates on the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.
ORMP At a Glance
Oramed Pharmaceuticals, Inc.
1185 Avenue of the Americas
New York, New York 10036
| Phone | 1-844-967-2633 | Revenue | 2.00M | |
| Industry | Pharmaceuticals: Major | Net Income | 63.24M | |
| Sector | Health Technology | Employees | 13 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ORMP Valuation
| P/E Current | 2.554 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 1.901 |
| Price to Sales Ratio | 60.447 |
| Price to Book Ratio | 0.56 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.279 |
| Enterprise Value to Sales | -2.088 |
| Total Debt to Enterprise Value | -0.198 |
ORMP Efficiency
| Revenue/Employee | 153,846.154 |
| Income Per Employee | 4,864,769.231 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.01 |
ORMP Liquidity
| Current Ratio | 6.983 |
| Quick Ratio | 6.983 |
| Cash Ratio | 6.596 |
ORMP Profitability
| Gross Margin | 0.65 |
| Operating Margin | -754.40 |
| Pretax Margin | 3,766.20 |
| Net Margin | 3,162.10 |
| Return on Assets | 32.756 |
| Return on Equity | 36.555 |
| Return on Total Capital | 31.531 |
| Return on Invested Capital | 36.482 |
ORMP Capital Structure
| Total Debt to Total Equity | 0.413 |
| Total Debt to Total Capital | 0.411 |
| Total Debt to Total Assets | 0.357 |
| Long-Term Debt to Equity | 0.27 |
| Long-Term Debt to Total Capital | 0.269 |